Summary of Maze Therapeutics Conference Call Company Overview - **Company**: Maze Therapeutics (NasdaqGM:MAZE) - **Industry**: Biopharmaceuticals focusing on kidney and metabolic diseases - **Pipeline**: Utilizes the Maze Compass platform to develop small-molecule precision medicines [1][2] Key Points from the Call AMKD Program Focus - **AMKD Prevalence**: 6 million patients in the U.S. have genetic variants causing AMKD, with 1 million having kidney disease; 250,000 could benefit from therapy [2] - **Patient Demographics**: 40% of AMKD patients are diabetic, while 60% are non-diabetic [2] MZE829 Therapy - **Differentiation**: MZE829 has a dual mechanism that blocks APOL1 pore assembly, potentially making it more effective than other treatments [3] - **Clinical Proof of Concept**: A 30% reduction in UACR (urine albumin-to-creatinine ratio) is considered clinically meaningful; MZE829 achieved a 36% mean reduction in UACR across broad AMKD patients [4][5] - **FSGS Results**: In patients with FSGS, MZE829 showed a 61.8% mean reduction in UACR [5] - **Safety Profile**: MZE829 was well-tolerated with no serious adverse events reported; common mild to moderate adverse events included headache and diarrhea [12] Clinical Trial Insights - **HORIZON Study**: Phase II trial included patients with broad AMKD, focusing on both diabetic and non-diabetic patients [7] - **Efficacy Analysis**: 50% of patients achieved a reduction greater than 30% in UACR; 48.6% mean reduction in non-diabetic patients [5][14] - **Diabetic Patient Data**: Early data shows promise for MZE829 in diabetic AMKD patients, with one patient showing a 47% reduction in proteinuria [15][16] Future Plans - **Pivotal Program**: Based on positive results, Maze plans to advance MZE829 into a pivotal program and will provide updates on regulatory progress [5][19] - **Additional Trials**: Maze is advancing MZE782 into two phase II trials for PKU and chronic kidney disease [18] - **Collaboration Milestone**: A $20 million milestone payment was triggered by Shionogi & Co. dosing the first patient in its phase II study for Pompe disease [19] Important Considerations - **Patient Enrollment**: The trial design allows for a broad AMKD population, including those with moderate disease and FSGS [8][9] - **Regulatory Engagement**: Maze is considering how to engage with regulators regarding the pivotal program and endpoint selection [63][64] - **Data Collection**: Continued enrollment in the HORIZON study will provide more data to refine the pivotal trial design and patient selection [104] Conclusion - Maze Therapeutics is positioned to make significant advancements in the treatment of AMKD with MZE829, showing promising efficacy and safety data. The company is focused on expanding its clinical programs and engaging with regulatory bodies to facilitate the development of its therapies [17][19]

Core Viewpoint - OnKure Therapeutics, Inc. is focused on developing novel precision medicines in oncology, with a particular emphasis on targeting biologically validated drivers of cancers that are underserved by existing therapies [1]. Company Overview - OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker OKUR [1]. - The company utilizes a structure- and computational chemistry-driven drug design platform to create a pipeline of tumor-agnostic candidates aimed at achieving optimal efficacy and tolerability [1]. - The lead program, OKI-219, is a selective PI3Kα inhibitor, and OnKure aims to become a leader in targeting oncogenic PI3Kα with multiple programs designed for best-in-class targeting of this key oncogene [1]. Upcoming Events - Nicholas Saccomano, Ph.D., President and CEO of OnKure, will present at the Leerink Partners Global Healthcare Conference on March 11, 2025, at 4:20 p.m. ET, with a live audio webcast available [3]. - OnKure will also participate in a fireside chat at the Stifel Targeted Oncology Forum, which will be held virtually on April 8-9, 2025 [3].